Marinomed applies for drug approval for new decongestant nasal spray in Europe

VIENNA - Sept. 8, 2020 - PRLog -- Marinomed Biotech AG has applied for approval of the new decongestant Carragelose^®nasal spray in a first group of EU countries. It is the first product from the Carragelose^®platform to be approved as a medicinal product. The spray aims to treat viral infections of the respiratory tract and reduce the swelling of the mucous membranes of the nose and throat, which enables free breathing through the nose. "With this decongestant nasal spray, we are expanding our successful Carragelose^®product range by including a non-prescription drug for the first time. This will give many people in Europe access to the advantages of Carragelose^®as a broad-spectrum virus blocker. As a company, we are strengthening our presence in the important market for decongestant nasal sprays," explains CEO Andreas Grassauer.

The nasal spray contains Carragelose^®and the decongestant xylometazoline. Carragelose^®forms a moisturizing protective film on the nasal mucosa and thus slows down the spread and multiplication of viruses. In addition, Carragelose^®supports the active ingredient xylometazoline in reducing the duration and intensity of symptoms in the event of a viral infection of the respiratory tract.


For further enquiries please contact:

Dr. Eva Prieschl-Grassauer

Chief Scientific Officer, Marinomed

Hovengasse 25, 2100 Korneuburg, Austria

T +43 2262 90300

E-Mail: eva.prieschl@marinomed.com

http://www.marinomed.com